Vera Therapeutics Advances Atacicept for Potential FDA Accelerated Approval
"The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN," said Marshall Fordyce, Founder and CEO of Vera Therapeutics. "During the first quarter, we made meaningful progress across key pre-commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to potentially be the first approved drug targeting both BAFF and APRIL in IgAN patients."
